Abstract:This article is a correction to: Vaccines for African swine fever: an update The final, formatted version of the article will be published soon. You have multiple emails registered with Frontiers: Please enter your email address: If you already have an account, please login You don't have a Frontiers account ? You can register here Corrigendum: Vaccines for African swine fever: an update Name of all authors as they appear in the published original article (INSERT ONLY IF correcting author names or adding authors. Insert the correct version of the author list) Affiliations of all authors as they appear in the published original version of the article (INSERT ONLY IF correcting affiliation(s) or adding affiliation(s). Insert the correct version of the affiliation(s)) * Correspondence: shanhu67@163.com; xlcai_99@163.com Keywords: same as original article Corrigendum on: Zhang H, Zhao S, Zhang H, Qin Z, Shan H and Cai X (2023). Vaccines for African swine fever: an update. Front. Microbiol. 14:1139494. doi: 10.3389/fmicb.2023.1139494 Incorrect Funding In the published article, there was an error in the Funding statement. [The last funding no. is in- correct. This work is based upon research funded by the Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project; No. 2020CXGC010801-02), the Shandong Province Agricultural Major Application Technology Innovation Project (No. SD2019XM003), the Project of Shandong Province Science and Technology Achievement Transfer Transformation Subsidy (No. 2021 LYXZ020), the Shandong Provincial Major Project of the New-Old Kinetic Energy Conversion [No. (2020)1220], and the Shandong Province Natural Science Foundation (No. ZR201910250090).]. The correct Funding statement appears below. FUNDING [This work is based upon research funded by the Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project; No. 2020CXGC010801-02), the Shandong Province Agricultural Major Application Technology Innovation Project (No. SD2019XM003), the Project of Shandong Province Science and Technology Achievement Transfer Transformation Subsidy (No. 2021 LYXZ020), the Shandong Provincial Major Project of the New-Old Kinetic Energy Conversion [No. (2020)1220], and the Project ZR2020MC185 supported by Shandong Provincial Natural Science Foundation.). The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Correction to: Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern

Correction to: Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines

Corrigendum: A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022

Corrigendum: Vaccines for African swine fever: an update

Corrigendum: COVIEdb: A Database for Potential Immune Epitopes of Coronaviruses.

Correction to "Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination" [The Lancet Regional Health - Europe 38 (2024) 100829]

Publisher Correction: Immunoglobulin Deposition on Biomolecule Corona Determines Complement Opsonization Efficiency of Preclinical and Clinical Nanoparticles

Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

Correction To: Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment

Corrigendum: High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

Erratum: Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review: Erratum

Erratum: Comprehensive Analysis of Antibody Recognition in Convalescent Humans from Highly Pathogenic Avian Influenza H5N1 Infection

Erratum: Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components

Correction to: All Infants Are at Risk of Developing Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection and Deserve Protection

Erratum: Comparison of two different canine anti-IgG antibodies for assessment of oligoclonal bands in cerebrospinal fluid and serum of dogs via isoelectric focusing followed by an immunoblot

Erratum: The HLA class-II immunopeptidomes of AAV capsids proteins

Correction: Li et al. Immunogenicity of Recombinant-Deficient Lactobacillus casei with Complementary Plasmid Expressing Alanine Racemase Gene and Core Neutralizing Epitope Antigen against Porcine Epidemic Diarrhea Virus. Vaccines 2021, 9 , 1084.

Correction to: A nanobody-horseradish peroxidase fusion protein-based competitive ELISA for rapid detection of antibodies against porcine circovirus type 2

Corrigendum: Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage

Corrigendum: SARS-CoV-2 evolution among patients with immunosuppression in a nosocomial cluster of a Japanese medical center during the Delta (AY.29 sublineage) surge

Corrigendum to "Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS"